{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-079452","form_type":"8-K","ticker":"CGON","cik":"0001991792","company_name":"CG Oncology, Inc.","filed_at":"2026-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.944905+00:00","generated_at":"2026-05-15T23:13:39.623062+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"confidence":"high","headline":"CG Oncology reports FY2025 net loss $161M; cash $903M provides runway to 1H 2029","bullets":["Q4 2025 net loss $41.3M ($0.52/share) vs $31.8M ($0.46/share) in Q4 2024.","Full-year 2025 net loss $161.0M ($2.08/share) vs $88.0M ($1.41/share) in FY2024.","Cash, equivalents, and securities ~$903M as of Feb 26, 2026; funded into first half 2029.","PIVOT-006 Phase 3 topline data in intermediate-risk NMIBC expected 1H 2026.","CORE-008 Cohort CX first combination results with gemcitabine in HR NMIBC expected 1H 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-079452","json":"https://secwatch.observer/filing/0001193125-26-079452.json","markdown":"https://secwatch.observer/filing/0001193125-26-079452.md","text":"https://secwatch.observer/filing/0001193125-26-079452.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1991792/000119312526079452/0001193125-26-079452-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1991792/000119312526079452/ck0001991792-20260227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T23:13:39.623062+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}